World Congress at ACG2017

Simultaneous Plenary Session 4C: IBD

73 - A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM

Wednesday, October 18
8:30 AM - 8:40 AM
Location: W414 (Level 4)



Award: 2017 ACG Governors Award for Excellence in Clinical Research

Category: IBD       

Jean-Frederic Colombel, MD1, Remo Panaccione, MD, FRCP2, Peter Bossuyt, MD3, Filip Baert, MD4, Tomas Vanasek, MD5, Ahmet Danalioglu, MD6, Gottfried Novacek, MD7, Alessandro Armuzzi, MD8, Xavier Hebuterne, MD9, Simon Travis, MD10, Silvio Danese, MD11, Walter Reinisch, MD12, William J. Sandborn, MD13, Paul Rutgeerts, MD14, Daniel Hommes, MD15, Stefan Schreiber, MD16, Ezequiel Neimark, MD17, Bidan Huang, MD17, Qian Zhou, MD17, Wan-Ju Lee, MD17, Joel Petersson, MD17, Kori Wallace, MD17, Anne M. Robinson, MD17, Roopal B. Thakkar, MD17, Geert D'Haens, MD, PhD18
1Icahn School of Medicine at Mount Sinai, New York, NY; 2University of Calgary, Department of Medicine, Calgary, AB, Canada; 3Imelda General Hospital, Bonheiden, Antwerpen, Belgium; 4AZ Delta Roeselare-Menen, Menen, Antwerpen, Belgium; 5Hepato-Gastroenterologie HK, Hradec Králové, Czech Republic; 6Bezmialem Vakif University, Istanbul, Turkey; 7Medical University of Vienna, Vienna, Austria; 8Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Lazio, Italy; 9Service de Gastroentérologie et Nutrition Clinique, Université de Nice-Sophia-Antipolis, Nice, Provence-Alpes-Cote d'Azur, France; 10Oxford University Hospitals, Oxford, United Kingdom; 11Istituto Clinico Humanitas, Milan, Italy; 12Medical University of Vienna, Hamilton, ON, Canada; 13University of California, La Jolla, CA; 14University of Leuven, Leuven, Belgium; 15University of California Los Angeles, Los Angeles, CA; 16University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany; 17AbbVie, Inc., North Chicago, IL; 18Academic Medical Center, Amsterdam, Noord-Holland, Netherlands
Introduction: Superior endoscopic outcomes in patients (pts) with moderate to severe Crohn's disease (CD) were achieved with tight control (T2T) of inflammation using biomarkers (C-reactive protein [CRP] and fecal calprotectin [FC]) compared to standard clinical management (CM) in CALM1. Differences in hospitalizations and serious disease-related complications between the study arms were analyzed.

Methods: Immunosuppressive and biologic-naive adults with CD; baseline CDAI>150-450 (+/- corticosteroids [CS]), active endoscopic CD (overall CDEIS>6 and sum of CDEIS subscores >6 in >1 segment with ulcers), and CRP>5 mg/L and/or FC>250 ug/g received prednisone burst/taper <8 weeks (wk), then randomized to T2T or CM at wk 9. Early randomization was allowed for some pts. Pts received <4 treatment options in a stepwise manner based on pre-defined success criteria: no treatment; 160/80 mg adalimumab (ADA) wks 0/2, 40 mg every other wk; ADA 40 mg wkly; ADA 40 mg wkly + azathioprine 2.5 mg/kg/day. CD-related hospitalizations, CD-related surgical procedures (major and non-major) and a composite endpoint of CD-related hospitalization or serious complication from randomization up to wk 48, were summarized as incidences or rates (events [E]/100 Patient Years [PY]). Chi-square test was used for differences between study arms. Hazard ratio (HR) of the composite endpoint was determined using Cox proportional hazard model. Any hospitalization was reported for all pts on or after randomization and up to 70 days after last dose.

Results: A total of 244 pts were randomized 1:1 to T2T and CM. BL mean ± SD age was 31.6 ± 11.7 years and 57.8% were female. The rate of CD-related hospitalizations after randomization was significantly lower with T2T compared to CM (Table). The rate of CD-related surgical procedures and the proportion of pts with CD-related hospitalization or serious complication were numerically lower in T2T compared to CM (Table). The risk of CD-related hospitalization or serious complication was numerically lower with T2T than CM: HR=0.7, 95% CI 0.4-1.3, P=0.249.

Discussion: A T2T approach using tight control of inflammation by biomarkers leads to a reduction of major adverse outcomes indicative for a detrimental course of disease, including CD-related hospitalizations. A longer study is needed to confirm these findings.

1. Colombel, JF et al. Gastroenterol. 2017;152(Suppl 1): S155.

Supported by Industry Grant: No

Disclosures: Does Disclose

Jean-Frederic Colombel: AbbVie – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Bristol-Myers Squibb – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Ferring Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Genentech – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Giuliani SPA – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Given Imaging – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Merck – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Millennium Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Pfizer – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Prometheus Laboratories – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Sanofi – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Schering-Plough Corporation – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Takeda – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Teva Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's Bureau. UCB Pharma (formerly Celltech Therapeutics) – Advisory Committee/Board Member, Consultant, Speaker's Bureau.
Remo Panaccione: AbbVie – Consultant, Speaker's Bureau. Amgen – Consultant, Speaker's Bureau. AstraZeneca – Consultant, Speaker's Bureau. Axcan Pharma (now Aptalis) – Consultant, Speaker's Bureau. Biogen Idec – Consultant, Speaker's Bureau. Bristol-Myers Squibb – Consultant, Speaker's Bureau. Centocor – Consultant, Speaker's Bureau. ChemoCentryx – Consultant, Speaker's Bureau. Eisai Medical Research Inc – Consultant, Speaker's Bureau. Elan Pharmaceuticals – Consultant, Speaker's Bureau. Ferring – Consultant, Speaker's Bureau. Genentech – Consultant, Speaker's Bureau. GlaxoSmithKline – Consultant, Speaker's Bureau. Janssen – Consultant, Speaker's Bureau. Merck Sharp & Dohme Corp – Consultant, Speaker's Bureau. Millennium Pharmaceuticals Inc (now Takeda) – Consultant, Speaker's Bureau. Ocera Therapeutics Inc – Speaker's Bureau. Otsuka America Pharmaceutical – Consultant, Speaker's Bureau. Prometheus Laboratories – Consultant, Speaker's Bureau. Schering-Plough Corporation – Consultant, Speaker's Bureau. Shire Pharmaceuticals – Consultant, Speaker's Bureau. Synta Pharmaceuticals Corp – Consultant, Speaker's Bureau. Teva – Consultant, Speaker's Bureau. UCB Pharma – Consultant, Speaker's Bureau. Warner Chilcott – Consultant, Speaker's Bureau.
Peter Bossuyt: AbbVie – Grant/Research Support, Speaker's Bureau. Dr Falk Benelux – Advisory Committee/Board Member. Hospira – Advisory Committee/Board Member. Janssen – Advisory Committee/Board Member. MSD – Advisory Committee/Board Member. Mundipharma – Advisory Committee/Board Member. Pfizer – Advisory Committee/Board Member. Roche – Advisory Committee/Board Member. Takeda – Speaker's Bureau. Vifor Pharma – Speaker's Bureau.
Filip Baert: Janssen – Consultant, Speaker's Bureau. AbbVie – Consultant, Grant/Research Support, Speaker's Bureau. Chiesi – Grant/Research Support. Falk – Consultant, Speaker's Bureau. Ferring – Consultant, Speaker's Bureau. Ipsen – Grant/Research Support. MSD – Consultant, Grant/Research Support, Speaker's Bureau. Mundipharma – Consultant, Speaker's Bureau. Pfizer – Consultant, Speaker's Bureau. Roche – Grant/Research Support. Takeda – Consultant, Speaker's Bureau. Vifor – Consultant, Speaker's Bureau.
Tomas Vanasek: Hospira – Advisory Committee/Board Member. Pfizer – Advisory Committee/Board Member. Takeda – Advisory Committee/Board Member, Speaker's Bureau.
Ahmet Danalioglu indicated no relevant financial relationships.
Gottfried Novacek: AbbVie – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Ferring – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Merck – Advisory Committee/Board Member, Consultant, Speaker's Bureau. MSD – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Takeda – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Vifor – Advisory Committee/Board Member, Consultant, Speaker's Bureau.
Alessandro Armuzzi: AbbVie – Advisory Committee/Board Member, Consultant, Speaker's Bureau. AstraZeneca – Speaker's Bureau. Biogen – Advisory Committee/Board Member, Consultant. Celltrion – Advisory Committee/Board Member, Consultant. Chiesi – Speaker's Bureau. Ferring – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Hospira – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Janssen – Advisory Committee/Board Member, Consultant. Lilly – Advisory Committee/Board Member, Consultant. MSD – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Mundipharma – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Otsuka – Speaker's Bureau. Pfizer – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Samsung – Advisory Committee/Board Member, Consultant. Sofar – Advisory Committee/Board Member, Consultant. Takeda – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Zambon – Speaker's Bureau.
Xavier Hebuterne: AbbVie – Advisory Committee/Board Member, Educational Activities. Arard – Educational Activities. Ferring – Educational Activities. Fresenius Kabi – Advisory Committee/Board Member, Educational Activities. Janssen – Advisory Committee/Board Member. Mayoli-Spindler – Educational Activities. MSD – Educational Activities. Nestlé – Educational Activities. Norgine – Educational Activities. Nutricia – Educational Activities. Takeda – Advisory Committee/Board Member, Educational Activities.
Simon Travis: AbbVie – Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau. Amgen – Advisory Committee/Board Member, Speaker's Bureau. Asahi – Advisory Committee/Board Member, Speaker's Bureau. Biogen – Advisory Committee/Board Member, Speaker's Bureau. Boehringer Ingelheim – Advisory Committee/Board Member, Speaker's Bureau. Bristol-Myers Squibb – Advisory Committee/Board Member, Speaker's Bureau. Celgene – Advisory Committee/Board Member, Speaker's Bureau. Chemocentryx – Advisory Committee/Board Member, Speaker's Bureau. Cosmo – Advisory Committee/Board Member, Speaker's Bureau. Ferring – Advisory Committee/Board Member, Speaker's Bureau. Giuliani SpA – Advisory Committee/Board Member, Speaker's Bureau. GlaxoSmithKline – Advisory Committee/Board Member, Speaker's Bureau. IOIBD – Grant/Research Support. Janssen – Advisory Committee/Board Member, Speaker's Bureau. Lilly – Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau. MSD – Advisory Committee/Board Member, Speaker's Bureau. Neovacs – Advisory Committee/Board Member, Speaker's Bureau. Norman Collisson Foundation – Grant/Research Support. Novartis – Speaker's Bureau. NovoNordisk – Advisory Committee/Board Member, Speaker's Bureau. NPS Pharmaceuticals – Advisory Committee/Board Member, Speaker's Bureau. Pfizer – Advisory Committee/Board Member, Speaker's Bureau. Proximagen – Speaker's Bureau. Receptos – Advisory Committee/Board Member, Speaker's Bureau. Shire – Advisory Committee/Board Member, Speaker's Bureau. Sigmoid Pharma – Advisory Committee/Board Member, Speaker's Bureau. Takeda – Advisory Committee/Board Member, Speaker's Bureau. Topivert – Advisory Committee/Board Member, Speaker's Bureau. UCB – Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau. VHsquared – Advisory Committee/Board Member, Speaker's Bureau. Vifor – Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau.
Silvio Danese: Merck & Co – Advisory Committee/Board Member, Consultant, Speaker's Bureau. AbbVie – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Actelion – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Alphawasserman – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Astra Zeneca – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Astra Zeneca – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Cellerix – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Cosmo Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Ferring – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Genentech – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Grunenthal – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Johnson&Johnson – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Millennium – Advisory Committee/Board Member, Consultant, Speaker's Bureau. NovoNordisk – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Nycomed – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Pfizer – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Pharmacosmos – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Salix – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Schering-Plough – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Takeda – Advisory Committee/Board Member, Consultant, Speaker's Bureau. UCB Pharma – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Vifor – Advisory Committee/Board Member, Consultant, Speaker's Bureau.
Walter Reinisch: 4SC – Advisory Committee/Board Member, Consultant. Abbott Laboratories – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Abbvie – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Aesca – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. AM Pharma – Advisory Committee/Board Member, Consultant. Amgen – Advisory Committee/Board Member, Consultant. Aptalis – Speaker's Bureau. Astellas – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Astra Zeneca – Advisory Committee/Board Member, Consultant. Avaxia – Advisory Committee/Board Member, Consultant. Bioclinica – Consultant. Biogen IDEC – Advisory Committee/Board Member, Consultant. Boehringer-Ingelheim – Advisory Committee/Board Member, Consultant. Bristol-Myers Squibb – Advisory Committee/Board Member, Consultant. Celgene – Advisory Committee/Board Member, Consultant. Cellerix – Advisory Committee/Board Member, Consultant. Celltrion – Speaker's Bureau. Centocor – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Chemocentryx – Advisory Committee/Board Member, Consultant. Covance – Consultant. Danone Austria – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Elan – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Ernest & Young – Consultant. Falk Pharma GmbH – Consultant, Grant/Research Support, Speaker's Bureau. Ferring – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Galapagos – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Genentech – Advisory Committee/Board Member, Consultant. Gilead – Consultant. Grünenthal – Advisory Committee/Board Member, Consultant. ICON – Consultant. Immundiagnostik – Speaker's Bureau. Index Pharma – Consultant. Inova – Consultant. Janssen – Advisory Committee/Board Member, Consultant. Johnson & Johnson – Advisory Committee/Board Member, Consultant. Kyowa Hakko Kirin Pharma – Advisory Committee/Board Member, Consultant. Lipid Therapeutics – Advisory Committee/Board Member, Consultant. Mallinckrodt – Consultant. MedImmune – Advisory Committee/Board Member, Consultant. Millenium – Advisory Committee/Board Member, Consultant. Mitsubishi Tanabe Pharma Corporation – Consultant, Speaker's Bureau. MSD – Consultant, Speaker's Bureau. Nestle – Advisory Committee/Board Member, Consultant. Novartis – Advisory Committee/Board Member, Consultant. Ocera – Advisory Committee/Board Member, Consultant. Otsuka – Advisory Committee/Board Member, Consultant, Speaker's Bureau. PDL – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Pfizer – Advisory Committee/Board Member, Consultant. Pharmacosmos – Advisory Committee/Board Member, Consultant, Speaker's Bureau. PLS Education – Speaker's Bureau. Procter & Gamble – Advisory Committee/Board Member, Consultant. Prometheus – Advisory Committee/Board Member, Consultant. Robarts Clinical Trial – Consultant. Roland Berger GmBH – Consultant. Schering-Plough – Advisory Committee/Board Member, Speaker's Bureau. Second Genome – Advisory Committee/Board Member, Consultant. Setpointmedical – Advisory Committee/Board Member, Consultant. Shire – Speaker's Bureau. Sigmoid – Consultant. Takeda – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Therakos – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Tigenix – Advisory Committee/Board Member, Consultant. UCB – Advisory Committee/Board Member, Consultant. Vifor – Consultant, Speaker's Bureau. Yakult – Speaker's Bureau. Zyngenia – Advisory Committee/Board Member, Consultant.
William Sandborn: AbbVie – Consultant, Grant/Research Support, Speaker's Bureau. ActoGeniX NV – Consultant. AGI Therapeutics, Inc. – Consultant. Alba Therapeutics Corporation – Consultant. Albireo – Consultant. Alfa Wasserman – Consultant. Amgen – Consultant. AM-Pharma BV, – Consultant. Anaphore – Consultant. Aptalis – Consultant. Athersys, Inc – Consultant. Atlantic Healthcare Limited – Consultant. BioBalance Corporation – Consultant. Boehringer Ingelheim, Inc – Consultant. Bristol-Myers Squibb – Consultant, Grant/Research Support, Speaker's Bureau. Celek Pharmaceuticals – Consultant. Celgene – Consultant. Cellerix SL – Consultant. Cerimon Pharmaceuticals – Consultant. ChemoCentryx – Consultant. CoMentis – Consultant. Coronado Biosciences – Consultant. Cosmo Technologies – Consultant. Cytokine PharmaSciences – Consultant. Eagle Pharmaceuticals – Consultant. Eisai Medical Research Inc – Consultant. Eli Lilly – Consultant. enGene, Inc – Consultant. EnteroMedics – Consultant. Exagen Diagnostics, Inc. – Consultant. Ferring Pharmaceuticals – Consultant. Flexion Therapeutics, Inc. – Consultant. Funxional Therapeutics, Limited – Consultant. Genentech – Consultant, Grant/Research Support. Genzyme Corporation – Consultant. Gilead Sciences – Consultant. Given Imaging – Consultant. GlaxoSmithKline – Consultant, Grant/Research Support. Human Genome Sciences – Consultant. Ironwood Pharmaceuticals – Consultant. Janssen – Consultant, Grant/Research Support, Speaker's Bureau. KaloBios Pharmaceuticals, Inc. – Consultant. Lexicon Pharmaceuticals – Consultant. Lycera Corporation – Consultant. Meda Pharmaceuticals – Consultant. Merck & Co. – Consultant. Merck Research Laboratories – Consultant. Merck Serono – Consultant. Millennium – Consultant, Grant/Research Support. Nisshin Kyorin Pharmaceuticals Co., Ltd – Consultant. Novartis – Grant/Research Support. Novo Nordisk A/S – Consultant. NPS Pharmaceuticals – Consultant. Optimer Pharmaceuticals – Consultant. Orexigen Therapeutics, Inc. – Consultant. PDL BioPharma – Consultant. Pfizer – Consultant, Grant/Research Support. Procter & Gamble – Consultant, Grant/Research Support. Prometheus Laboratories – Consultant. ProtAb Limited – Consultant. PurGenesis Technologies, Inc. – Consultant. Receptos – Consultant. Relypsa, Inc – Consultant. S.L.A. Pharma (UK) Limited – Consultant. Salient Pharmaceuticals – Consultant. Salix Pharmaceuticals, Inc. – Consultant. Santarus – Consultant. Shire Pharmaceuticals – Consultant, Grant/Research Support. Sigmoid Pharma Limited – Consultant. Sirtris Pharmaceuticals, Inc. (a GSK company) – Consultant. Targacept – Consultant. Teva Pharmaceuticals – Consultant. Therakos – Consultant. Tillotts Pharma AG – Consultant. TxCell SA – Consultant. UCB Pharma – Consultant, Grant/Research Support. Vascular Biogenics Limited (VBL) – Consultant. Viamet Pharmaceuticals – Consultant. Warner Chilcott UK Limited – Consultant.
Paul Rutgeerts: Abbvie – Consultant, Grant/Research Support, Speaker's Bureau. Bristol-Myers Squibb – Consultant. Centocor – Consultant, Grant/Research Support, Speaker's Bureau. Merck – Consultant. MSD – Grant/Research Support, Speaker's Bureau. Takeda – Consultant. UCB Pharma – Consultant, Grant/Research Support, Speaker's Bureau.
Daniel Hommes: AbbVie – Consultant, Grant/Research Support. AstraZeneca – Consultant, Grant/Research Support. Bristol-Myers Squibb – Consultant, Grant/Research Support. Cellerix – Consultant, Grant/Research Support. Centocor – Consultant, Grant/Research Support. Chemocentryx – Consultant, Grant/Research Support. ELAN – Consultant, Grant/Research Support. Falk – Consultant, Grant/Research Support. Ferring – Consultant, Grant/Research Support. Genentech – Consultant, Grant/Research Support. Giuliani Pharma – Consultant, Grant/Research Support. IBM – Consultant, Grant/Research Support. Janssen – Consultant, Grant/Research Support. Johnson & Johnson – Consultant, Grant/Research Support. Leo Pharma – Consultant, Grant/Research Support. MSD – Consultant, Grant/Research Support. Novimmune – Consultant, Grant/Research Support. Otsuka – Consultant, Grant/Research Support. PDL BioPharma – Consultant, Grant/Research Support. Philips – Consultant, Grant/Research Support. Procter & Gamble – Consultant, Grant/Research Support. Roche – Consultant, Grant/Research Support. Schering Plough – Consultant, Grant/Research Support. Serono – Consultant, Grant/Research Support. Tramedico – Consultant, Grant/Research Support. UCB Pharma – Consultant, Grant/Research Support.
Stefan Schreiber: AbbVie – Consultant. Falk Pharma – Consultant. Ferring – Consultant. Genentech – Consultant. GSK – Consultant. MSD – Consultant. Pfizer – Consultant. Shire – Consultant. Takeda – Consultant.
Ezequiel Neimark: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Bidan Huang: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Qian Zhou: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Wan-Ju Lee: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Joel Petersson: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Kori Wallace: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Anne M. Robinson: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Roopal B. Thakkar: AbbVie – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).
Geert D''Haens: AbbVie – Consultant, Grant/Research Support, Speaker's Bureau. ActoGeniX – Consultant. AIM – Consultant. Boehringer Ingelheim GmbH – Consultant. Centocor – Consultant. Chemo Centryx – Consultant. Cosmo Technologies – Consultant. Dr Falk Pharma – Consultant, Grant/Research Support. Elan Pharmaceuticals – Consultant. enGene – Consultant. Ferring – Consultant, Speaker's Bureau. Galapagos – Consultant. Giuliani SpA – Consultant. Given Imaging – Consultant, Grant/Research Support. GlaxoSmithKline – Consultant. Janssen Biologics – Consultant. MSD – Grant/Research Support, Speaker's Bureau. Neovacs – Consultant. Norgine – Speaker's Bureau. Novo Nordisk – Consultant. Otsuka – Consultant. PDL BioPharma – Consultant. Pfizer – Consultant. PhotoPill – Grant/Research Support. Receptos – Consultant. Salix – Consultant. Schering-Plough – Consultant. SetPoint – Consultant. Shire Pharmaceuticals – Consultant, Speaker's Bureau. Takeda – Consultant. Tillotts Pharma – Consultant, Speaker's Bureau. Tramedico – Speaker's Bureau. UCB Pharma – Consultant, Speaker's Bureau. Versant – Consultant. Vifor Pharma – Consultant.

Table.



























  T2T CM P value
CD-related hospitalization, events (E/100PY) 14 (13.2) 29 (28.0) P=0.021
CD-related surgeries, eventsa (E/100PY) 7 (6.6)  9 (8.7) P=0.582
CD-related hospitalization or serious complicationb, n (%) 18 (14.8) 25 (20.5) P=0.240

amajor CD-related surgeries: bowel resection, ostomy, by-pass, strictureplasty, and surgical drainage of abdominal/pelvic abscess; non-major CD-related surgeries: debridment, abscess drainage, seton placement, fistulotomy, placement of a TPN access line


bserious complication: presence of abscess, fistula or stricture, skin and ocular extra-intestinal manifestation, and serious adverse drug reaction

Citation: . A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM. Program No. 73. World Congress of Gastroenterology at ACG2017 Meeting Abstracts. Orlando, FL: American College of Gastroenterology.

Send Email for Daniel Hommes


Assets

73 - A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM